Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to $807,000.

  • Aclaris Therapeutics' Depreciation & Amortization (CF) fell 38.55% to $110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $495,000, marking a year-over-year decrease of 44.51%. This contributed to the annual value of $807,000 for FY2024, which is 6.49% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Depreciation & Amortization (CF) is $807,000, which was down 6.49% from $863,000 recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Depreciation & Amortization (CF) registered a high of $1.3 million during FY2020, and its lowest value of $797,000 during FY2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $807,000 (2024), whereas its average is $822,333.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first slumped by 79.34% in 2020, then grew by 8.28% in 2023.
  • Aclaris Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $1.3 million in 2020, then crashed by 30.29% to $923,000 in 2021, then dropped by 13.65% to $797,000 in 2022, then climbed by 8.28% to $863,000 in 2023, then dropped by 6.49% to $807,000 in 2024.